Supplements · Metabolic & Cardiometabolic

green tea decreases LDL cholesterol

In plain terms: Does green tea lower cholesterol?

Strong support Supplements 🔬 Includes disconfirming

RefutedContestedStrong support

consensus score 0.68

Modestly, yes. Across many trials green tea nudges LDL and total cholesterol down a small amount (roughly 5-9 mg/dL LDL). It is a minor but fairly consistent effect - a helpful habit, not a replacement for cholesterol treatment.

📅 Last reviewed: 2026-07-15 ⓘ

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: All trials, pooled (Meta-analysis)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

11 support 2 contradict 0 tested null 1 mixed · 14 sources, 13 independent groups · 1 superseded — pooled inside a review, counted once

What the evidence shows

Green tea modestly but fairly consistently lowers total and LDL cholesterol across many RCTs and meta-analyses (typically ~5-9 mg/dL LDL). A few recent analyses find no effect in specific subgroups, but with fuller sourcing the weight of evidence supports a small, real reduction - helpful but minor, not a substitute for cholesterol treatment.

Cochrane agrees with us see how our grade compares ▾

Cochrane review 2013 · not GRADE-rated per outcome Agrees with our grade

authors advise 'some caution' (few trials, risk of bias, green-tea LDL result not stable to sensitivity analysis)

“The limited evidence suggests that tea has favourable effects on CVD risk factors, but due to the small number of trials contributing to each analysis the results should be treated with some caution. Green tea produced statistically significant reductions in LDL cholesterol (MD -0.64 mmol/L, 95% CI -0.77 to -0.52; 4 trials, 327 participants), but only a small number of studies contributed and the results were not stable to sensitivity analysis.”

Why we agree: we reached the same direction independently, from our own appraisal of 14 sources. Two methods landing in the same place is a stronger signal than either alone.

What is Cochrane, and why trust it?

Cochrane produces systematic reviews: instead of running a new study, they gather every trial ever done on a question, judge how well each was run, and pool the results. They take no commercial or industry funding, which is why the medical community treats their reviews as a gold standard — and why we check our own verdicts against theirs.

About Cochrane ↗ · Get involved / support ↗

Read the Cochrane review ↗

The evidence (18)

Source	Grade	Stance	Quality	Finding
Zheng XX, Xu YL, Li SH, Liu XX, Hui R, Huang XH 2011 · Am J Clin Nutr	meta-analysis	supports	high	Meta 14 RCTs: total cholesterol -7.2 mg/dL and LDL -2.19 mg/dL (modest); no HDL change.
Gholami F, Antonio J, Iranpour M, Curtis J, Pereira F 2024 · J Int Soc Sports Nutr	meta-analysis	contradicts	moderate	Meta-analysis of RCTs randomising green tea/catechin vs placebo on top of supervised exercise in overweight/obese adults; LDL pool is 5 of the 10 trials: 'EX+GT had no significantly greater effect on LDL reduction compared to EX+P [SMD = 0.03 (95% CI −0.73 to 0.82), p = 0.92; 5 trials]', I2 = 81.98%. Null on the directional claim -> contradicts. Abstract misprints LDL as 'SMD = -1.44'; the results section value (0.03) is used. No Egger test reported for LDL.
Fan J, Yun S, Qu Z, Liu Z, Gong Y 2026 · Curr Res Food Sci	mechanism	supports	moderate	Narrative review: 'This review is a structured narrative review rather than a formal systematic review.' EGCG mechanisms (micelle disruption, AMPK) only; no LDL outcome of its own. Review — zero weight.
Erba D, Riso P, Bordoni A, Foti P, Biagi PL, Testolin G 2005 · J Nutr Biochem	RCT	supports	low	Small 42-day trial (~250 mg catechins/d): LDL fell 119.9 -> 106.6 mg/dL (p<.05).
Liu C et al 2025 · medRxiv	meta-analysis	supports	moderate	Network meta-analysis of 44 RCTs on green tea, exercise, and combinations for overweight/obesity; green tea combined with aerobic exercise was rated optimal for reducing TC and LDL among the compared interventions.
Basu A, Sanchez K, Leyva MJ, Wu M, Betts NM, Aston CE, Lyons TJ 2010 · J Am Coll Nutr	RCT	supports	moderate	RCT (metabolic syndrome): green tea reduced LDL/TC and lipid peroxidation.
Sławińska P, Raczkowska E 2026 · Nutrients	observational	supports	low	Narrative review of matcha/green tea catechins covering glucose, lipid profile, weight, and microbiota effects broadly across in vitro/in vivo studies; no pooled LDL/TC effect size given.
Maron DJ, Lu GP, Cai NS, Wu ZG, Li YH, Chen H, Zhu JQ, Jin XJ, Wouters BC, Zhao J 2003 · Arch Intern Med	RCT	supports	moderate	RCT n=240: theaflavin-enriched green tea extract TC -11.3%, LDL -16.4% (theaflavin-enriched product).
Kosik-Bogacka DI, Piotrowska K 2025 · Nutrients	observational	supports	low	Narrative review of matcha/EGCG human and animal trials in MASLD; reports beneficial effects on body weight, cholesterol levels, and liver metabolism/function noted across studies, even short-term.
Kim A, Chiu A, Barone MK, Avino D, Wang F, Coleman CI, Phung OJ 2011 · J Am Diet Assoc	meta-analysis	supports	high	Meta 20 RCTs (n=1415): TC -5.46, LDL -5.30 mg/dL; no HDL/TG change.
Xu R, Yang K, Li S, Dai M, Chen G 2020 · Nutr J	meta-analysis	supports	high	Meta RCTs: green tea significantly reduced total cholesterol and LDL.
Ghoflchi S, Mohammadi H, Teimouri M, Imani M, Hosseini H 2025 · Clin Ther	meta-analysis	contradicts	low	Meta-analysis of RCTs in metabolic syndrome: LDL-C SMD -0.45 (P=.25) and total cholesterol SMD -0.38 (P=.19), both non-significant. Subgroup 'benefits' each come from subsets whose k and n the abstract does not report: <8 weeks LDL-C SMD -0.83, <3000 mg/d LDL-C SMD -0.83, women LDL-C SMD -1.25. Authors state 'overall high heterogeneity and publication bias'; k, total n and all confidence intervals absent from the abstract.
Wang Y, Xia H, Yu J, Sui J, Pan D, Wang S, Liao W, Yang L, Sun G 2023 · Heliyon	meta-analysis	mixed	low	Meta 11 RCTs (overweight/obese): reduced waist & triglycerides, raised HDL, but NO significant LDL or total-cholesterol effect.
Chen IJ, Liu CY, Chiu JP, Hsu CH 2016 · Clin Nutr	RCT	supports	moderate	RCT: high-dose EGCG (857 mg/d) reduced LDL alongside weight loss in central obesity. ↩ SUPERSEDED — pooled in the review above, counted once
Pormlikul T, On-Nom N, Suttisansanee U, Temviriyanukul P, Trachootham D, Khemthong C, Muangpracha N, Thangsiri S, Praengam K, Chupeerach C 2025 · Food science & nutrition	RCT	supports	moderate	6-week double-blind placebo-controlled RCT in 60 dyslipidemia adults (n=30 green tea, n=30 placebo); total cholesterol fell 4.96% and LDL fell 7.98% in the green tea group vs placebo.
Quezada-Fernández P, Trujillo-Quiros J, Pascoe-González S, Trujillo-Rangel WA, Cardona-Müller D, Ramos-Becerra CG, Barocio-Pantoja M, Rodríguez-de la Cerda M, Nérida Sánchez-Rodríguez E, Cardona-Muñóz EG, García-Benavides L, Grover-Páez F 2019 · Int J Food Sci Nutr	RCT	supports	low	Small RCT (n=20 T2D on statins): improved lipid profile + arterial stiffness.
Hoseini E, Razavi BM, Alavi MS, Hosseinzadeh H, Roohbakhsh A 2025 · Avicenna J Phytomed	animal	supports	low	Full-text re-read 2026-08-25 (PMC12441192 JATS XML in the local fulltext-cache, 104,503 bytes; no network fetch — the source note said provenance: abstract). Controlled rat experiment, 14 groups of n=5 (70 male Wistar rats), isolated purified ECG or EGCG given INTRAPERITONEALLY once daily for 11 days alongside olanzapine 5 mg/kg. On the claim's own object, LDL moved at ONE dose only for both compounds: 'Concomitant administration of olanzapine and 40 mg/kg of ECG reduced LDL and cholesterol levels significantly' and 'Similarly, EGCG at the dose of 40 mg/kg reduced serum TG, cholesterol, and LDL levels compared to the olanzapine group'. The previously stored 'at multiple doses' was a TRIGLYCERIDE result: TG fell at all three ECG doses ('treatment with ECG in combination with olanzapine substantially reduced serum TG levels at all doses') while LDL did not — a broader endpoint's better result reported under the narrower claim. Every LDL comparison in the paper is against the concurrently-dosed olanzapine group; the text reports no catechin-alone-vs-control LDL contrast (the available text does not say), so this is protection against drug-induced dyslipidemia rather than LDL-lowering in a normal state. HDL is a split near-null on the same figures: 'Also, ECG enhanced HDL levels at 20 mg/kg' but for EGCG 'it did not change HDL levels mitigated by olanzapine'. Quality low on reliability, not size: n=5 per group, no blinding described, no multiplicity handling, and the paper's concluding paragraph credits 'EGC (20 mg)', a compound never administered.
Momose Y, Maeda-Yamamoto M, Nabetani H 2016 · Int J Food Sci Nutr	meta-analysis	supports	high	Systematic review 17 RCTs: EGCG reduced LDL -9.29 mg/dL.

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.